Vale SA
VALE
D.R. Horton
DHI
Taylor Morrison Home
TMHC
Petroleo Brasileiro SA Petrobras
PBR
Lennar Corp
LEN
US Stock MarketDetailed Quotes
CMMB Chemomab Therapeutics
- 1.430
- -0.070-4.67%
Trading Mar 18 13:48 ET
26.96MMarket Cap-1.66P/E (TTM)
1.489High1.425Low36.90KVolume1.450Open1.500Pre Close53.42KTurnover0.31%Turnover RatioLossP/E (Static)18.86MShares2.55052wk High1.99P/B16.90MFloat Cap0.57952wk Low--Dividend TTM11.82MShs Float184.000Historical High--Div YieldTTM4.29%Amplitude0.420Historical Low1.447Avg Price1Lot Size
Chemomab Therapeutics News
Oppenheimer Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $11
Chemomab Therapeutics (CMMB) Gets a Buy From Oppenheimer
Chemomab Therapeutics Analyst Ratings
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Raises Target Price to $7
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Raises Target Price to $7
Analysts Are Bullish on Top Healthcare Stocks: Chemomab Therapeutics (CMMB), Blueprint Medicines (BPMC)
Oppenheimer Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $11
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $4
Oppenheimer Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Cuts Target Price to $11
Chemomab Therapeutics Analyst Ratings
Roth MKM Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $9
Roth MKM Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $9
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $4
Chemomab Therapeutics (CMMB) Gets a Buy From Oppenheimer
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $4
Roth MKM Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Raises Target Price to $9
Oppenheimer Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Raises Target Price to $13
Chemomab Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Chemomab Therapeutics (CMMB), Fate Therapeutics (FATE) and Disc Medicine (IRON)
Analysts Offer Insights on Healthcare Companies: Andlauer Healthcare Group (OtherANDHF), ACADIA Pharmaceuticals (ACAD) and Chemomab Therapeutics (CMMB)
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.